Orphan Drugs are significantly impacting the health care market. A recent independent report analyzes the key market elements and challenges, providing some guidance to pharmaceutical companies and payers on developing strategies for survival and growth.
The report indicates that the orphan drug market is experiencing robust growth due to increased awareness, improved diagnostics, advancements in biotechnology, and supportive government policies. Financial incentives such as market exclusivity, tax credits, and grants continue to encourage pharmaceutical companies to develop treatments for rare diseases.
Moreover, leading factors driving this growth include heightened awareness, advancements in diagnostics, biotechnology, and supportive government policies and programs. The orphan drug pipeline is expanding, particularly with Cell and Gene therapy candidates, despite high development costs, limited patient populations, and regulatory challenges. Notably, demand in emerging global markets is having a significant reciprocal impact on the global market.
Orphan Drugs Market Size to Expand at a CAGR of 9.7% During the Forecast Period of 2024-2030
CLICK HERE for more detail on the referenced report
